Roy A. Whitfield, Director at NEKTAR THERAPEUTICS (NKTR), bought 35,000 shares at $17.95 ($628K) on 2017-08-10, disclosed to the SEC on 2017-08-14.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| Filing → |
| ILMN | SELL | 2016-08-15 | $669K | — | Filing → |
| ILMN | SELL | 2016-06-15 | $534K | — | Filing → |
| ILMN | SELL | 2016-04-14 | $680K | — | Filing → |